Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing

PRECIGEN, INC.

Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).
Precigen grants Catalent exclusive rights for external commercial fill/finish manufacturing of the product in the Territory.
Initial term of three years, automatically renews annually unless 12-month termination notice given.
Precigen commits to minimum batch purchases per contract year as specified in the Plan Document.
Pricing subject to annual adjustment based on labor, utilities, and overhead costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.